China News Service, October 25 (Reporter Chen Jing) Bladder cancer is one of the most common malignant tumors of the male urinary system.
The reporter learned on the 25th that the team of Professor Chen Haige from the Department of Urology, Renji Hospital, Shanghai Jiaotong University School of Medicine, was the first to develop a precision detection kit based on multiple genes. Effective means of individualized precision treatment.
It is understood that the current gold standard for diagnosing and monitoring bladder cancer is cystoscopy, but because of its invasiveness and high price, it restricts its clinical application and promotion.
Urine tumor markers, exfoliated cytology and other non-invasive examinations lack sensitivity and specificity, and cannot reveal tumor gene phenotypes, which brings certain difficulties to clinical screening and accurate diagnosis of bladder cancer.
In recent years, related next-generation sequencing technologies (NGS) are gradually being promoted in clinical practice. Many studies have proved that urine tumor DNA (utDNA) and circulating tumor DNA (ctDNA) detection has the potential for development in patients with bladder cancer, but There is still a lack of research on its diagnostic effect in clinical practice.
The research team told reporters that a complete verification of it is a scientific research problem that the research team strives to solve.
It is reported that the relevant research results were published in the form of cover papers in the well-known urology journal "American Journal of Urology".
It is reported that after testing, the kit can diagnose and monitor 92% of malignant lesions. At the same time, because of its non-invasive and convenient characteristics, it can be used as an early detection and screening tool for bladder cancer.
Professor Chen Haige pointed out that in the future, further experiments will be conducted to confirm its diagnostic effect and enter the transformation of clinical results, which will bring the gospel to more patients.
(over)